Last week, Kleiner Device Labs (KDL) picked up two media mentions worth mentioning…
First came from the financial publisher Benzinga titled “This Medical Startup Could Disrupt The $14 Billion Spinal Fusion Market: Last Call To Invest.”
The second came from a well known industry publication called Becker’s Spine Review titled “Spine surgeon’s startup wants a slice of the $14B spinal fusion market.”
If you’ve been following the KDL story, you already know that Dr. Kleiner – the founder and CEO – has performed over 6,000 spinal surgeries during his 25 year career.
He also has personally had three spinal surgeries performed on him as a patient!
Not only that, but he’s invested $2 million of his own money and has his name sake on the company.
Why should investors care? All things considered, investing in founders with this much ”skin in the game” – both financially and reputationally – is preferable to the opposite.
And perhaps more importantly, he’s been able to recruit a team of industry veterans to help lay the foundation for future growth.
According to management:
The two largest costs for KDL that will directly translate to success are product development and building a salesforce.
From a cost perspective, the KDL team has been highly effective at developing products.
According to Pitchbook, the average cost of developing a MedTech device and achieving 510(k) Clearance is $31 million.
According to Management, they’ve deployed ~$5m total to develop two devices that have achieved 510(k) Clearance!
Not to mention the 23 patents they’ve acquired to secure their technology.
But it’s not enough to simply “build a better mousetrap”…
In order to create shareholder value, the company needs to effectively sell their products into a complex sales cycle.
That’s why they hired Mike Hughes to be their Chief Commercial Officer!
Not only does Mike bring his two decades of experience building medical sales teams, he brings a rolodex of potential customers and industry contacts.
Watch Equifund interview Mike here.
Considering an Investment in Kleiner Device Labs?
If so, you’ll want to review their offering listed on the Equifund Crowd Funding Portal by going here.
Currently, KDL can raise up to $1.07 million under their current Form-C filing (they are currently at ~$850k in commitments).
Management has also indicated they will be closing this round once the first surgery has been completed with the new KG2.
They may or may not continue to raise more capital via regulation crowdfunding.
Put another way, this may be your last chance to invest in Kleiner Device Labs at the current valuation.
Sincerely,
Jake Hoffberg – Publisher
Equifund
